OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The interplay between HIV and COVID-19: summary of the data and responses to date	128
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	59
What constitutes a syndemic? Methods, contexts, and framing from 2019	55
Eliminating HIV reservoirs for a cure: the issue is in the tissue	37
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	37
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV	33
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV	30
Exosomes in HIV infection	25
Frailty: the current challenge for aging people with HIV	23
Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies	22
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV	20
Cardiovascular toxicity of contemporary antiretroviral therapy	19
Syndemic theory, structural violence and HIV among African–Americans	18
HIV persistence in lymph nodes	18
The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals	18
Immunological effector mechanisms in HIV-1 elite controllers	18
Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission	17
Identifying and managing infectious disease syndemics in patients with HIV	17
Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection	17
The OATH Syndemic: opioids and other substances, aging, alcohol, tobacco, and HIV	15
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	15
Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors	15
In-vitro and in-vivo models for hepatitis B cure research	14
Adapting digital health interventions for the evolving HIV landscape: examples to support prevention and treatment research	13
HIV care during the coronavirus disease-2019 pandemic in Shenzhen, China	13

Doravirine: its role in HIV treatment	13
Technologies for HIV-1 drug resistance testing: inventory and needs	13
Recent insights into Fc-mediated effector responses to HIV-1	13
Scaling up preexposure prophylaxis to maximize HIV prevention impact	12
The future of long-acting agents for preexposure prophylaxis	12
The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence	12
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	12
Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa	11
HIV and cardiovascular disease: the role of inflammation	11
Syndemics of HIV with mental illness and other noncommunicable diseases: a research agenda to address the gap between syndemic theory and current research practice	11
Let's talk chronic disease: can differentiated service delivery address the syndemics of HIV, hypertension and diabetes?	11
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors	11
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV	10
Characterizing the role of intersecting stigmas and sustained inequities in driving HIV syndemics across low-to-middle-income settings	10
“Go”, “No Go,” or “Where to Go”; does microbiota dictate T cell exhaustion, programming, and HIV persistence?	10
New vector and vaccine platforms: mRNA, DNA, viral vectors	9
Beyond criminalization: reconsidering HIV criminalization in an era of reform	8
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication	8
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	8
Hidden in plain sight: sex and gender in global pandemics	8
Treatment of coronavirus disease 2019	8
From surviving to thriving: the current status of the behavioral, social, and psychological issues of aging with HIV	8
Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research	8
Cardiovascular disease risk in women living with HIV	8
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	8
Recent data on adipose tissue, insulin resistance, diabetes and dyslipidaemia in antiretroviral therapy controlled HIV-infected persons	8
Advances in simian--human immunodeficiency viruses for nonhuman primate studies of HIV prevention and cure	7
Advances in cell and gene therapy for HIV disease: it is good to be specific	7
Promises and challenges: cabotegravir for preexposure prophylaxis	7
Chimeric antigen receptor T-cell therapy for HIV cure	7
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	7
COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research	7
Potential and demonstrated impacts of the COVID-19 pandemic on sexually transmissible infections: Republication	7
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	7